Stoke Therapeutics, Inc. — Earnings Quality Grade F
STOK · Healthcare
Major red flags
Screening Summary
Management Signals
Financial Trends
Revenue & Net Income ($B)
Margins (%)
18-Point Screening
Revenue Quality
DSO 12 days, change -5 days YoY
AR growth 255.9% vs revenue growth 404.5%
Revenue 404.5%, CFFO 152.5%. Cash follows revenue
Expense Quality
No material inventory
CapEx growth 230.0% vs revenue 404.5%. Normal
Insufficient data
Insufficient data
Cash Flow Quality
CFFO < Net Income for 3 consecutive years
FCF $0.0B, FCF/NI = -6.52
Accruals ratio = -12.5%. Low accruals
Cash $0.3B covers debt $0.0B
Balance Sheet Health
No goodwill. Clean balance sheet
Debt/EBITDA = -0.2x. Healthy
Other assets -68.5% vs revenue 404.5%. Normal
No write-off data
Acquisition Risk
FCF after acquisitions negative for 2/3 years
No goodwill
Manipulation Score
Insufficient data
Portfolio monitoring
Monitor STOK continuously
The full checks and model details are free to read. Use Watchlist to track your holdings; Pro adds automatic quarterly rescoring, risk-event email alerts, scans up to 50 tickers, and export workflows.
Altman Z-Score
Generated from public financial data using forensic accounting frameworks. Not investment advice. Data: Yahoo Finance · 2026-04-25